Increasing Role of Biomarkers for Prostate Cancer and Bladder Cancer Detection

Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol. 1997 Sep;4(3):400-405.
http://www.ncbi.nlm.nih.gov/pubmed/12735818

Friedrich MG, Hellstern A, Toma MI, et al. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumorrecurrence? Eur Urol. 2003 Feb;43(2):146-50; discussion 150-1.
http://www.ncbi.nlm.nih.gov/pubmed/12565772

Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn. 2003 Jul;3(4):507-19.
http://www.ncbi.nlm.nih.gov/pubmed/12877389

Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection ofurothelial carcinoma in urine. J Urol. 2002 May;167(5):2001-6.
http://www.ncbi.nlm.nih.gov/pubmed/11956427

Karakiewicz PI, Benayoun S, Zippe C, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinomaof the bladder. BJU Int. 2006 May;97(5):997-1001.
http://www.ncbi.nlm.nih.gov/pubmed/16542342

Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998 Oct;4(10):2511-20.
http://www.ncbi.nlm.nih.gov/pubmed/9796985

Leyh H, Marberger M, Conort P, et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis andmonitoring of bladder cancer. Eur Urol. 1999 Jan;35(1):52-6.
http://www.ncbi.nlm.nih.gov/pubmed/9933795

Mian C, Pycha A, Wiener H, et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999 May;161(5):1486-9.
http://www.ncbi.nlm.nih.gov/pubmed/10210378

Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol. 2001 Sep;35(4):280-2.
http://www.ncbi.nlm.nih.gov/pubmed/11676352

Shariat SF, Casella R, Wians FH Jr, et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol. 2004 Mar;45(3):304-13; author reply 313.
http://www.ncbi.nlm.nih.gov/pubmed/15036675

Shariat SF, Zippe C, Lüdecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patientswith Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 2005 May;173(5):1518-25.
http://www.ncbi.nlm.nih.gov/pubmed/15821471

Shariat SF, Marberger MJ, Lotan Y, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol. 2006 Sep;176(3):919-26; discussion 926.
http://www.ncbi.nlm.nih.gov/pubmed/16890655

Shariat SF, Karam JA, Lotan Y, et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008 Spring;10(2):120-35.
http://www.ncbi.nlm.nih.gov/pubmed/18660854

Shelfo SW, Soloway MS. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol. 1997;15(2):107-11.
http://www.ncbi.nlm.nih.gov/pubmed/9144900

Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patientswith bladder cancer and atypical or negative urine cytology. J Urol. 2003 Jun;169(6):2101-5.
http://www.ncbi.nlm.nih.gov/pubmed/12771727

Vriesema JL, Atsma F, Kiemeney LA, et al. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology. 2001 Sep;58(3):367-71.
http://www.ncbi.nlm.nih.gov/pubmed/11549482